Douglas Dundonald, founder and CEO of Tharos, joins UK Investor Magazine to explain why his company is taking a fundamentally different approach to animal gut health. Rather than adding bacteria like conventional probiotics, Tharos’s patented “anabiomic” technology, a natural barley extract, works in the upper gut to improve nutrient absorption and starve harmful bacteria of fuel.
Learn more about Tharos on Republic here.
In this conversation, Douglas discusses the clinical evidence behind the platform, the institutional credibility earned through the company’s equine brand EquiNectar (trusted by the Household Cavalry, the Met Police and UK Border Force), and the launch of CaniNectar into a global animal supplement market worth over $4 billion.
He also sets out the commercial model built around a professional referral network of vets and trainers, the path from £726k revenue in 2025 toward £25.6m by 2029, and the company’s current EIS-qualifying raise on Republic.